We’re pleased to share that BiomOrgan has jointly initiated the newly formed Biomedical New Paradigm Innovation Alliance, together with Revvity, XtalPi, and Xellar Biosystems. This alliance was created to accelerate next‑generation drug discovery and build a more integrated, human‑relevant R&D ecosystem. As part of this collaborative effort, BiomOrgan will lead organoid model development and organoid‑based screening for AI‑discovered drug candidates, powered by our proprietary organoid technology platform.

By working closely with partners across biotech and AI, the alliance aims to streamline early‑stage drug development, improve translational predictability, and open new pathways for innovative therapeutic discovery.

We’re excited to co‑create this platform with our partners and help shape a new paradigm for biopharmaceutical innovation.